Clinical Trial Results:
Comparison of ARIXTRA™ in lower LImb Superficial Thrombophlebitis with placebO (CALISTO).
An International, Multicentre, Randomised, Double-blind, Placebo-controlled, Two-parallel Group, Phase III Study to Evaluate the Efficacy and Safety of ARIXTRA (2.5 mg subcutaneously) for the Treatment of Patients with Acute Symptomatic Isolated Superficial Thrombophlebitis of the Lower Limbs to prevent Thromboembolic Complications
Summary
|
|
EudraCT number |
2006-004774-27 |
Trial protocol |
DE NL EE HU LV GR FR SK CZ IT GB BG ES |
Global completion date |
31 Jul 2009
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 Jul 2016
|
First version publication date |
07 Jul 2016
|
Other versions |
|
Summary report(s) |
108053-FDAAA-Result-Summary |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.